Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 May;131(6):740-749.
doi: 10.1111/1471-0528.17737. Epub 2023 Dec 27.

Nd:YAG/Er:YAG dual laser compared with topical steroid to treat vulvar lichen sclerosus: A randomised controlled trial

Irena Zivanovic  1 , Marianne Gamper  1 , Debra Fesslmeier  1 , Claudia Walser  1 , Sigrid Regauer  2 , Volker Viereck  1
Affiliations
Randomized Controlled Trial

Nd:YAG/Er:YAG dual laser compared with topical steroid to treat vulvar lichen sclerosus: A randomised controlled trial

Irena Zivanovic et al. BJOG. 2024 May.

Abstract

Objective: To evaluate the efficacy and safety of a novel non-ablative Nd:YAG/Er:YAG dual laser treatment for vulvar lichen sclerosus (LS) in comparison with the recommended first-line therapy with topical steroid.

Design: A randomised investigator-initiated active-controlled trial.

Setting: Single tertiary referral centre.

Population: Women with vulvar LS.

Methods: Randomisation (2:1) to Nd:YAG/Er:YAG laser therapy or topical clobetasol proprionate therapy. Four laser treatments at 0, 1, 2 and 4 months or decreasing doses of steroid for 6 months.

Main outcome measures: The primary outcome was the change in objective validated clinical LS score in the laser arm between baseline and 6 months. Secondary outcomes were laser tolerability/safety, symptom scores and patient satisfaction.

Results: Sixty-six women were included, 44 in the laser group and 22 in the steroid group. The total LS score decreased by -2.34 ± 1.20 (95% CI -2.71 to -1.98) in women treated with laser compared with a decrease of -0.95 ± 0.90 (95% CI -1.35 to -0.56) in those receiving steroid applications (p < 0.001). Laser treatment was safe and well tolerated. Subjective severity scores (on visual analogue scale) and vulvovaginal symptoms questionnaire scores improved similarly for the laser and steroid arms without significant differences between the two treatments. Patient satisfaction was higher in the laser arm than in the steroid arm (p = 0.035).

Conclusions: Non-ablative dual Nd:YAG/Er:YAG laser therapy was safe and significantly improved clinical outcome and subjective symptoms at the 6-month follow up. This suggests that laser may be a promising alternative to corticosteroid therapy. However, the authors caution regular follow ups because of the premalignant nature of the disease.

Keywords: clobetasol propionate; laser safety; lichen sclerosus; non‐ablative Nd:YAG/Er:YAG laser therapy; prospective randomised controlled trial; steroid therapy.

PubMed Disclaimer

References

REFERENCES

    1. Lewis FM, Tatnall FM, Velangi SS, Bunker CB, Kumar A, Brackenbury F, et al. British Association of Dermatologists guidelines for the management of lichen sclerosus, 2018. Br J Dermatol. 2018;178:839–853.
    1. Kirtschig G, Kinberger M, Kreuter A, Simpson R, Günthert A, van Hees C, et al. EuroGuiDerm guideline lichen sclerosus version 1. European Centre for Guidelines Development. Zurich, Switzerland: The European Dermatology Forum (EDF); 2023. p. 1–128.
    1. Lee A, Bradford J, Fischer G. Long‐term management of adult vulvar lichen sclerosus: a prospective cohort study of 507 women. JAMA Dermatol. 2015;151:1061–1067.
    1. De Luca DA, Papara C, Vorobyev A, Staiger H, Bieber K, Thaci D, et al. Lichen sclerosus: the 2023 update. Front Med (Lausanne). 2023;10:1106318.
    1. Bizjak Ogrinc U, Sencar S, Luzar B, Lukanovic A. Efficacy of non‐ablative laser therapy for lichen sclerosus: a randomized controlled trial. J Obstet Gynaecol Can. 2019;41:1717–1725.

Publication types

LinkOut - more resources